FDA updates Paxlovid (nirmatrelvir/ritonavir) label to include COVID-19 rebound information and drug interaction clarifications
FDA approved a label update for Paxlovid (nirmatrelvir/ritonavir; Pfizer) adding a new section on COVID-19 symptom rebound observed in a minority of patients 2–8 days after completing the 5-day course. The update also clarifies contraindicated drug interactions via CYP3A4, adds new guidance on use in moderate renal impairment (eGFR 30–60 mL/min), and updates the pregnancy data section.
Paxlovid (nirmatrelvir 150 mg/ritonavir 100 mg; Pfizer) ↗ received an FDA label update on 8 October 2026. Three key changes were made: (1) a new Section 5.3 on COVID-19 symptom and viral rebound, documenting that a minority of patients experience return of symptoms 2–8 days after completing the 5-day course without confirmed reinfection; (2) updated DDI guidance clarifying CYP3A4 interaction risks specifically for ritonavir's pharmacokinetic boosting mechanism; and (3) revised Section 8.6 (renal impairment) with clearer guidance for moderate impairment (eGFR 30–60 mL/min) requiring dose reduction.
COVID-19 rebound: what is known
Post-Paxlovid COVID-19 rebound was first described in case reports in 2022 and confirmed in larger datasets. The updated label clarifies that rebound occurs in approximately 10–15% of treated patients based on post-marketing data, is generally mild and self-limiting, and does not appear to require re-treatment in most cases. The mechanism is incompletely understood but may involve incomplete viral clearance in immunologically privileged compartments. The CDC COVID-19 treatment guidance ↗ has been updated correspondingly to advise clinicians and patients that symptom recurrence within 8 days of completing Paxlovid does not routinely warrant additional antiviral therapy.
Drug interactions: ritonavir CYP3A4 inhibition
Ritonavir in Paxlovid is dosed as a pharmacokinetic booster — it inhibits CYP3A4, increasing nirmatrelvir exposure ~10-fold. This potent CYP3A4 inhibition creates a broad drug interaction profile during the 5-day treatment course. The updated label now more explicitly categorises interactions: contraindicated (alfuzosin, ranolazine, colchicine in renal/hepatic impairment, lovastatin, simvastatin, pimozide, lurasidone, ergot derivatives); require dose adjustment or temporary discontinuation (tacrolimus, cyclosporine, warfarin, some antidepressants). For patients on immunosuppressants or anticoagulants, level monitoring or temporary dose adjustment is critical. See FDA DDI labelling table ↗.
Renal impairment dosing
The updated label provides more granular renal dosing guidance. For eGFR 30–60 mL/min: nirmatrelvir 150 mg (one tablet) + ritonavir 100 mg (one tablet) twice daily (instead of the standard 300 mg/100 mg twice daily). For eGFR <30 mL/min or patients on dialysis: Paxlovid is not recommended. The Cockcroft-Gault formula using actual body weight is recommended for eGFR estimation in the context of Paxlovid prescribing. For methodology, see the renal dosing adjustments guide and updated DailyMed label ↗.
FAQ
What triggers an FDA label update?
Label updates can be triggered by post-market safety data from the FAERS database ↗, new clinical trial results, manufacturer-initiated reviews, or FDA-directed safety communications. The FDA can require label changes under 21 CFR 314.81 or negotiate them with manufacturers. See the FDA Safety-related Labeling Changes (SrLC) database ↗ for a full history.
Where is the updated label published?
Updated labels are published on DailyMed (NLM) ↗ and Drugs@FDA ↗. DailyMed is typically the most current source, as manufacturers submit label updates there directly.